Abstract:Colorectal cancer (CRC) remains the second cause of death by cancer worldwide and its survival is currently estimated at 60%1. There is therefore a crucial need to identify biomarkers and new targets for therapy. In 90% of CRC, the Wnt/β-catenin pathway is constitutively activated due to mutations of β-catenin, APC (Adenomatous Polyposis Coli) or axin-12. These alterations cause an accumulation of β-catenin and lead to an over-transcription of target genes involved in tumorigenesis3-4. Studies of our team pointed out an overexpression of the Protein Tyrosine Kinase 7 (PTK7) in CRC, an event associated with metastatic development, reduced metastases-free survival, and resistance to chemotherapy. In CRC cells, the pseudokinase PTK7 has pro-metastatic and pro-migratory functions, and thus appears to be a promising new therapeutic target5-6. The role of PTK7 in the Wnt/β-catenin pathway has been demonstrated in several studies7-8. Our group identified β-catenin as a partner of PTK7. We selected a first series of small molecules inhibitors targeting PTK7/β-catenin interaction9. This strategy could represent, in the future, a new therapeutic strategy to inhibit CRC cell growth dependent on the Wnt signaling pathway. However, the compounds identified had weak activity, with an IC50 of around 10-25 mM. We have set up a new method with SYNSIGHT to select more potent chemical inhibitors targeting PTK7/β-catenin in CRC in order to counteract the Wnt/β-catenin signaling pathway deregulation. References: 1Colorectal cancer (Source : Globocan 2020); 2Cancer Genome Atlas Network. Nature. 2012; 3He, T. C. et al. Science. 1998; 4Tetsu, O. & McCormick, F. Nature. 1999; 5Lhoumeau, A.-C. et al. PLOS ONE. 2015; 6Lhoumeau, A.-C. et al. J. Immunol. 2016; 7Puppo, F. et al. EMBO Rep. 2011; 8Peradziryi, H. et al. EMBO J. 2011; 9Ganier, L. et al. ACS Chem. Biol. 2022; 10Daulat, A. M. & Borg, J.-P. Trends Cancer. 2017; 11Stamos, J. L. & Weis, W. I. Cold Spring Harb. Perspect. Biol. 2013. Citation Format: Jean-Paul Borg, Manon Pierre, Laetitia Ganier, Avais Daulat, Amandine Molliex, Julien Duez, Maxime Sanchez, Etienne Lallemand, Anthony Goncalves, Guillaume Bollot. New strategies to target the pseudokinase receptor PTK7 in the Wnt pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1807.

Pyrvinium doubles against WNT-driven cancer

Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α

The Casein kinase 1α agonist pyrvinium attenuates Wnt-mediated CK1α degradation via interaction with the E3 ubiquitin ligase component Cereblon

Pyrvinium Sensitizes Clear Cell Renal Cell Carcinoma Response to Chemotherapy Via Casein Kinase 1α-Dependent Inhibition of Wnt/β-Catenin

Newly Developed CK1-Specific Inhibitors Show Specifically Stronger Effects on CK1 Mutants and Colon Cancer Cell Lines

Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy

Effect of Suppressing Tankyrases on Canonical Wnt Pathway: A New Target for the Treatment of Cancer

Pharmacologic Inhibition of β-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor

Casein kinase 1α-dependent inhibition of Wnt/β-catenin selectively targets nasopharyngeal carcinoma and increases chemosensitivity

Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation

Abstract 1807: New strategies to target the pseudokinase receptor PTK7 in the Wnt pathway

Hyper activation of β-catenin signalling induced by IKKε inhibition thwarts colorectal cancer cell proliferation.

Targeting XBP1-mediated Β-Catenin Expression Associated with Bladder Cancer with Newly Synthetic Oridonin Analogues.

PP2A Inhibitors Suppress Migration and Growth of PANC-1 Pancreatic Cancer Cells Through Inhibition on the Wnt/β-catenin Pathway by Phosphorylation and Degradation of Β-Catenin

New Synthesis of Pyrvinium That Inhibits the Β-Catenin/tcf4 Pathway

Pyrvinium attenuates Hedgehog signaling downstream of smoothened

Pharmacological Inhibition of Β-Catenin/bcl9 Interaction Overcomes Resistance to Immune Checkpoint Blockades by Modulating T Reg Cells

A Protac Peptide Induces Durable Beta-Catenin Degradation And Suppresses Wnt-Dependent Intestinal Cancer

WNT Pathway Inhibitor Pyrvinium Pamoate Inhibits the Self-Renewal and Metastasis of Breast Cancer Stem Cells.

Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer

Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1